Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII

Koji Yada; Keiji Nogami; Kenichi Ogiwara; Masaru Shibata; Midori Shima

doi:10.1160/TH10-12-0781

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(06): 989-998
DOI: 10.1160/TH10-12-0781

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII

Koji Yada

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

,

Keiji Nogami

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

,

Kenichi Ogiwara

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

,

Masaru Shibata

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

,

Midori Shima

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

› Author Affiliations

Abstract

Summary

Factor (F)VIIa/tissue factor (TF) rapidly activates FVIII activity by proteolysis at Arg³⁷² and Arg⁷⁴⁰, and subsequently inactivates FVIIIa activity by proteolysis at Arg³³⁶, although this activation is weaker than that by thrombin. The effects of anti-FVIII inhibitor antibodies on these reactions remain unknown, however. In this study, 13 of anti-FVIII inhibitor antibodies recognising the A2 or C2 domain were prepared. None of them, irrespective of epitope specificity, significantly affected FVIIa/TFcatalysed FVIII activation in one-stage clotting assays. Anti-A2 and anti-C2 type 2 antibodies had little effect on the inactivation phase. Anti-C2 type 1 antibodies, however, modulated inactivation by 40–60% of that seen with control IgG, suggesting that the activity of FVIIIa generated by FVIIa/TF persisted in the presence of this specific type of inhibitor. SDS-PAGE analysis demonstrated that all antibodies had little effect on FVIIa/TF-catalyzed proteolysis at Arg³⁷² and Arg⁷⁴⁰. Anti-C2 type 1, however, significantly delayed cleavage at Arg³³⁶ in dose-dependent manners. Neither anti-A2 nor anti-C2 type 2 affected this reaction, and the findings were consistent with the results of the functional assays. In addition, anti-C2 monoclonal antibodies with type 1 and 2 demonstrated similar patterns of reaction as the anti-C2 polyclonal antibodies in FVIIa/TF-mediated FVIII mechanisms. We demonstrated that FVIIa/TF activated FVIII even in the presence of anti-FVIII antibodies, but inactivation patterns appeared to depend on inhibitor type. It could be important to determine the characteristic of these inhibitor antibodies for prediction of their effects on FVIIa-related FVIII reactions, and the results could have significant therapeutic implications.

Note: An account of this work was presented at the 51st annual meeting of the American Society of Hematology, 2009, New Orleans, LA, USA. This work was supported by grants for MEXT KAKENHI 21591370 in Japan and Bayer Hemophilia Award program.

Keywords

FVIII - FVIII inhibitor antibodies - FVIIa/TF - activation/inactivation - cleavage

Full Text

References

References
1 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
2 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13.
3 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
4 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
5 Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
6 Nogami K, Wakabayashi H, Schmidt K. et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278: 1634-1641.
7 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425.
8 Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
9 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-226.
10 Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75: 1069-1073.
11 Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haemotologica 2000; 85: 7-13.
12 Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-1109.
13 Scandella D, de Graaf S, Mahoney S. et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6156.
14 Scandella D, Mattingly M, de Graaf S. et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626.
15 Zhong D, Saenko EL, Shima M. et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-142.
16 Meeks SL, Healey JF, Parker ET. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
17 Meeks SL, Healey JF, Parker ET. et al. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 2008; 112: 1151-1153.
18 Nogami K, Shima M, Nishiya K. et al. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism. Thromb Haemost 2002; 87: 459-465.
19 Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-29830.
20 Nogami K, Saenko EL, Takeyama M. et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372. Br J Haematol 2008; 140: 433-443.
21 Soeda T, Nogami K, Matsumoto T. et al. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost 2010; 8: 2494-2503.
22 Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995; 270: 8546-8552.
23 Takeshima K, Smith C, Tait J. et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 788-794.
24 Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
25 Foster PA, Fulcher CA, Houghten RA. et al. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-128.
26 Scandella D, Timmons L, Mattingly M. et al. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-671.
27 Mimms LT, Zampighi G, Nozaki Y. et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
28 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254.
29 Kasper CK, Aledort LM, Counts RB. et al. More uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
30 Soeda T, Nogami K, Nishiya K. et al. The factor VIIIa C2 domain (residues 2228–2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem 2009; 284: 3379-3388.
31 Nogami K, Shima M, Hosokawa K. et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275: 25774-25780.
32 Nogami K, Shima M, Hosokawa K. et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274: 31000-31007.
33 Healey JF, Barrow RT, Tamim HM. et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-3709.
34 Nogami K, Shima M, Nakai H. et al. Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloanti-bodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol 1999; 107: 196-203.
35 Takeyama M, Nogami K, Saenko EL. et al. Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain. Thromb Haemost 2009; 102: 645-655.
36 Nogami K, Saenko EL, Takeyama M. et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372. Br J Haematol 2008; 140: 433-443.
37 Nogami K, Nishiya K, Saenko EL. et al. Identification of a plasmin-interactive site within the A2 domain of the factor VIII heavy chain. Biochim Biophys Acta 2008; 1784: 753-763.
38 Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010; 151: 381-386.